These inhibitors function by binding to PCSK9, preventing it from interacting with LDL receptors on liver cells. This process increases the number of LDL receptors available to clear LDL-C from the blood, thus reducing overall cholesterol levels. By targeting this specific pathway, PCSK9 inhibitors offer a novel mechanism of action compared to traditional statins.
